Daily non-political popular news in brief.

Physician ties to drug industry stronger than ever

A new national survey finds that physician ties to drug manufacturers are a standard part of practice.

Read more »

Keywords: physician, ties, drug, industry, stronger

« Previous | Next »

Similar news on "Physician ties to drug industry stronger than ever":

1. RAND study finds religiosity can be an important tool in preventing the spread of HIV-AIDS
   04-03-2007 · EurekAlert!
   HIV-positive people who say religion is an important part of their lives are likely to have fewer sexual partners and engage in high-risk sexual behavior less frequently than other people with the virus that causes AIDS, according to a study issued today by the RAND Corp. As a result, people with HIV who have stronger religious ties are less likely to spread the virus, according to the study by the nonprofit research organization.
   Similar news · Read more »
   
2. Building stronger bones, 1 stem cell at a time
   01-24-2008 · EurekAlert!
   Mesenchymal stem cells are capable of giving rise to various cell types through a process known as differentiation. A new study has determined that the anti-tumor drug bortezomib targets MSCs and leads to bone cell-specific differentiation. These data led the authors to suggest that Bzb might be a novel therapy for bone loss in individuals with osteoporosis and those with cancers accompanied by severe bone disease, such as myeloma.
   Similar news · Read more »
   
3. Annals of Internal Medicine Tip Sheet for May 15, 2007
   05-14-2007 · EurekAlert!
   In this issue: "Drug Market Research Goes Back 50 Years, Aided by Physicians and Physician Organizations," "Managing Depression in Older Adults Is Linked to Lower Death Rates," and "Fibromyalgia Review: Patients Experience Pain Differently From Norm."
   Similar news · Read more »
   
4. Lessons from Vioxx case -- New approach needed to restore faith in pharmaceutical industry
   01-19-2007 · EurekAlert!
   The pharmaceutical industry, academia and government agencies need to work together to restore faith in drug development, say doctors in this weeks' BMJ. They argue that the recent litigation over the drug Vioxx, produced by Merck and Co. Inc., has highlighted the failings of the current system, which can be open to abuse.
   Similar news · Read more »
   
5. Influence of drug companies on medical literature
   09-24-2007 · EurekAlert!
   In this issue: Physician awareness of drug cost: a systematic review; Bladder cancer decision analysis; and How much of the medical literature is shaped behind the scenes by drug companies?
   Similar news · Read more »
   
6. Physician-scientist urges improved drug regulation to ensure heart safety of non-heart drugs
   12-28-2007 · EurekAlert!
   Current regulatory policies should be strengthened to ensure acceptable cardiovascular safety of drugs developed primarily for non-cardiovascular medical problems, according to a recent presentation made by Dr. Jeffrey Borer, an authority in cardiovascular medicine and surgery at NewYork-Presbyterian Hospital/Weill Cornell Medical Center in New York City.
   Similar news · Read more »
   
7. Ghost authorship of industry funded drug trials is common
   01-15-2007 · EurekAlert!
   Ghost authorship is the failure to name, as an author, an individual who has made a substantial contribution to a scientific article. A study of 44 industry-initiated trials from Denmark in the 1990s found evidence of ghost authorship for 33 trials, which increased to 40 if a person qualifying for authorship was just acknowledged rather than being named as an author.
   Similar news · Read more »
   
8. UWM research helps industry make stronger, lighter and cheaper alloys
   10-27-2006 · EurekAlert!
   Industry is actively pursuing new materials that push the boundaries for strength, reliability and weight. UWM's Pradeep Rohatgi delivers. Now, he is perfecting technologies that will enable parts from these materials to be manufactured more rapidly than foreign competitors can -- and on site, away from a factory.
   Similar news · Read more »
   
9. Mayo Clinic Cancer Center -- individualizing treatment for multiple myeloma patients
   12-10-2006 · EurekAlert!
   Researchers at Mayo Clinic Cancer Center, in cooperation with industry partners, have, for the first time, identified tumor specific alterations in the cellular pathway by which the multiple myeloma drug bortezomib (Velcade) works, and they have identified nine new genetic mutations in cancer cells that should increase a patient's chance of responding to the agent.
   Similar news · Read more »
   
10. Drug industry increasingly influences breast cancer research
    02-26-2007 · EurekAlert!
    Breast cancer treatment trials supported by the pharmaceutical industry are more likely to report positive results than non-sponsored studies, according to a study to be published in the April 1, 2007 issue of CANCER, a peer-reviewed journal of the American Cancer Society.
    Similar news · Read more »